Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
garetosmab + trevogrumab
- Development stage
- Discontinued
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN2477 + REGN1033 is a combination therapy developed by Regeneron Pharmaceuticals for the treatment of sporadic inclusion body myositis (sIBM). The combination consists of two monoclonal antibodies: garetosmab (REGN2477), which targets activin A, and trevogrumab (REGN1033), which targets myostatin (GDF-8). Both activin A and myostatin are members of the TGF-beta superfamily that act as negative regulators of muscle mass. By blocking these ligands, the combination therapy aims to inhibit the myostatin/activin receptor signaling pathway, thereby promoting muscle growth and improving muscle function in patients with sIBM. A Phase 2 clinical trial was initiated to evaluate the efficacy of the combination on total lean mass, but Regeneron cancelled the study in late 2018.
- Other names
- garetosmab + trevogrumab
02
Targets
GDF8 (Myostatin)Activin A / Activin AB / Activin AC
Beyond the preview
Go deeper on garetosmab + trevogrumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on garetosmab + trevogrumab.